Intervention

DE-111 ophthalmic solution

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 3 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials3

Recruiting0

Common conditions3

Lead sponsors shown1

Clinical trials

3 shown

DE-111 Against Timolol Ophthalmic Solution 0.5%NCT01342094 · 2011-05-01

COMPLETED

DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular HypertensionNCT01343082 · 2011-05-01

COMPLETED

DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%NCT01342081 · 2011-05-01

COMPLETED

Common conditions

Ocular Hypertension2 Open Angle Glaucoma2 Open Angle Glaucoma or Ocular Hypertension1

Leading sponsors

Santen Pharmaceutical Co., Ltd. 3

Trial status mix

COMPLETED3

Phase mix

PHASE33

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.